Table 4.
Clinical picture and frequency of anti‐PBF A24.2 peptide CTLs in PBMC of patients with PBF‐positive osteosacoma
| Participants | Status of tumor bearing | Chemotherapy | Total number of tested wells | Number of tetramer‐ positive wells | Number of PMBC | %CD8 | Number of CD8+ cells per pool | Frequency † |
|---|---|---|---|---|---|---|---|---|
| Patient | ||||||||
| 26 | (P)‡, M | underway | 62 | 14 | 200 000 | 17 | 34 000 | 7 × 10−6 |
| 36 | P | not done | 194 | 6 | 210 000 | 23 | 48 000 | 6 × 10−7 |
| 76 | (P) | underway | 19 | 2 | 200 000 | 9 | 18 000 | 6 × 10−6 |
| 78 | (P) | underway | 62 | 1 | 200 000 | 15 | 30 000 | 5 × 10−7 |
| 79 | (P), M | underway | 28 | 0 | 200 000 | 15 | 30 000 | <1 × 10−6 |
| 80 | (P) | underway | 160 | 15 | 290 000 | 20 | 58 000 | 2 × 10−6 |
| 81 | (P) | underway | 149 | 5 | 200 000 | 3 | 6000 | 6 × 10−6 |
| 82 | (P) | underway | 132 | 3 | 200 000 | 4 | 8000 | 3 × 10−6 |
| 83 | P | underway | 40 | 5 | 200 000 | 25 | 50 000 | 3 × 10−6 |
†
Frequency of anti‐PBF A24.2 CTLs among CD8+ cells.
‡
‡Parentheses indicate that the tumor had been present previously but was free at the time blood sample was taken. CTLs, cytotoxic T lymphocytes; M, metastatic tumor; P, primary tumor; PBF, papillomavirus binding factor; PMBC, peripheral blood mononuclear cell.